New approach for Parkinson's diagnosis with flux compensator

October 21, 2016, Forschungsverbund Berlin e.V. (FVB)
For several years, the "Molecular Imaging" research group at the FMP led by physicist Leif Schröder has been developing new MRI methods that rely on just such a "flux compensator" and has demonstrated the impressive potential of this method. Now, it is to be used in a next step that aims at the possible early detection of Parkinson’s disease. Credit: FMP/Silke Oßwald

A new project for the early detection of Parkinson's disease with strongly magnetized xenon gas has been initiated at FMP. The team led by physicist Leif Schröder has received a three-year grant from the Michael J. Fox Foundation for Parkinson's Research. This research aims to make a link between science fiction and pioneering basic research.

One year ago, "Back to the Future Day" (10/21/2015) was celebrated worldwide to commemorate the film trilogy "Back to the Future" and Marty McFly's 30-year time travel. This was also an opportunity to take a look into the future of science. In particular, the lead actor, Michael J. Fox, reflected on advances in medicine since 1985 in the context of his Foundation which is dedicated to the study of Parkinson's disease.

The Leibniz-Institut für Molekulare Pharmakologie (FMP) has now launched a project for the possible early detection of Parkinson's that shares an important feature with Doc Brown's famous DeLorean. It shows how unconventional ideas play an important role both in science fiction as well as in new scientific approaches. An essential component for the implementation of time travel in the movies was a so-called "flux compensator," which later became a phrase of some popularity in German slang, an erroneous translation of the "flux capacitor" from the English original. But what kind of flux can be influenced or compensated with this device?

In the movie, it permitted a compression of the time flux to enable time travel. Another type of flux is magnetic flux which is used to describe the strength of magnetic fields. For certain applications, there is indeed a desire for a kind of compensator, namely for a relatively low magnetic flux to match conditions as under very strong fields. One application is magnetic resonance imaging (MRI) where one would aim to apply even stronger magnetic fields to achieve sharper images and faster data acquisition. However, since this approach is technically limited, scientists have been developing methods in which the detected molecules are manipulated such that they emit a significantly enhanced signal – just as if they would be in a much stronger magnetic field.

One of these methods works with very intense infrared laser light ultimately to enhance the magnetization of the harmless noble gas xenon. The obtained signal strengths allow for the detection of formerly inaccessibly small amounts of substance. For several years, the "Molecular Imaging" research group at the FMP led by physicist Leif Schröder has been developing new MRI methods that rely on just such a "flux compensator" and has demonstrated the impressive potential of this method. Now, it is to be used in a next step that aims at the possible early detection of Parkinson's disease. The sensitivity of the technique would otherwise only be achieved with a 20,000-fold stronger magnetic field, which would only occur on a neutron star.

In the project supported by The Michael J. Fox Foundation with a grant of $349,500 USD over three years, the team will develop a new type of contrast agent for MRI with the artificially magnetized xenon. It involves a molecular unit known to bind to the protein α-synuclein. Deposits of this protein are considered to be one of the causes of Parkinson's disease. The contrast agent first detects the presence of the protein by a signal change of the xenon before the formation of harmful deposits takes place. Thus, it also has a protective effect, since the later impacts of the deposits can be prevented.

In the tradition of Campus Buch, the latest methods in physics in the life sciences will be used to bridge the gap between the legendary flux compensator and potential applications supported by The Foundation. Examples of this tradition include the early use of neutron generators in radiation biology and therapy, and the work of the Ruska brothers concerning electron microscopy.

Related Stories

Recommended for you

Parkinson's disease 'jerking' side effect detected by algorithm

January 8, 2018
A mathematical algorithm that can reliably detect dyskinesia, the side effect from Parkinson's treatment that causes involuntary jerking movements and muscle spasms, could hold the key to improving treatment and for patients ...

New brainstem changes identified in Parkinson's disease

January 4, 2018
A pioneering study has found that patients with Parkinson's disease have more errors in the mitochondrial DNA within the brainstem, leading to increased cell death in that area.

Caffeine level in blood may help diagnose people with Parkinson's disease

January 3, 2018
Testing the level of caffeine in the blood may provide a simple way to aid the diagnosis of Parkinson's disease, according to a study published in the January 3, 2018, online issue of Neurology, the medical journal of the ...

Researchers shed light on why exercise slows progression of Parkinson's disease

December 22, 2017
While vigorous exercise on a treadmill has been shown to slow the progression of Parkinson's disease in patients, the molecular reasons behind it have remained a mystery.

Robotic device improves balance and gait in Parkinson's disease patients

December 19, 2017
Some 50,000 people in the U.S. are diagnosed with Parkinson's disease (PD) every year. The American Institute of Neurology estimates there are one million people affected with this neurodegenerative disorder, with 60 years ...

New findings point to potential therapy for Parkinson's Disease

December 19, 2017
A new study, published in Proceedings of the National Academy of Sciences (PNAS), sheds light on a mechanism underlying Parkinson's disease and suggests that Tacrolimus—an existing drug that targets the toxic protein interaction ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.